---
title: "Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3… — Eli Lilly — DecisionGateway"
description: "statement by Eli Lilly, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1de6e-50ce-7eaa-8f6c-b50cddbb4cd0"
meta:
  "og:description": "statement by Eli Lilly, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3… — Eli Lilly — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3 ATTAIN-OSA trial for adults with obesity and moderate-to-severe obstructive sleep apnea.**

A statement by [**Eli Lilly**](https://dgw.tmarket.io/actors/01a1d799-ee63-796c-972b-e41e8b55f59a). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *Eli Lilly says Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3 ATTAIN-OSA trial for adults with obesity and moderate-to-severe obstructive sleep apnea.*

pattystraphousePublished 2026-11-09 [ Read source](https://t.me/pattystraphouse/1264)

[**Eli Lilly dossier **](https://dgw.tmarket.io/actors/01a1d799-ee63-796c-972b-e41e8b55f59a)

## **Discussion**

## **Related claims**

[**If regulators accept the sleep-apnea data, Lilly gains a second disease-specific use for an oral obesity drug and a cleaner pitch to patients who do not want injections.**MY READ · prediction](https://dgw.tmarket.io/claims/01a1de6e-5122-756f-a303-e5ee7c04cfd4) [**At 52 weeks, the apnea-hypopnea index fell by an average 19.1 events per hour with Foundayo versus 3.6 with placebo.**Lilly · statement](https://dgw.tmarket.io/claims/01a1de6e-50e2-767f-bcd2-25432d6fed5e) [**This widens Foundayo's commercial lane beyond weight loss alone.**MY READ · prediction](https://dgw.tmarket.io/claims/01a1de6e-5112-7882-bd64-d12955f147d6) [**Novo Nordisk announced that the marketing application for its new drug CagriSema (cagrilintide and semaglutide injection) for long-term weight management has been accepted by the National Medical Products Administration.**诺和诺德 · statement](https://dgw.tmarket.io/claims/01a1d24c-483f-793d-9b6b-be462fc1a0f8) [**CagriSema consists of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.**界面新闻 · statement](https://dgw.tmarket.io/claims/01a1d24c-485a-7af6-9fa1-7aa87fd66188) [**What changes this read: regulators reject the weight-loss-independent analysis, safety or adherence weakens in full publication, or payers restrict coverage despite an approval.**MY READ · prediction](https://dgw.tmarket.io/claims/01a1de6e-5143-7da5-87cc-9fb0ade79e1d)

## **More claims by Eli Lilly**

No other claims by this actor on record.

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,500+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1de6e-50ce-7eaa-8f6c-b50cddbb4cd0#webpage","@type":"WebPage","description":"statement by Eli Lilly, recorded recently — verbatim quote and source citation.","name":"Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3… — Eli Lilly — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1de6e-50ce-7eaa-8f6c-b50cddbb4cd0","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1de6e-50ce-7eaa-8f6c-b50cddbb4cd0#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1de6e-50ce-7eaa-8f6c-b50cddbb4cd0"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1de6e-50ce-7eaa-8f6c-b50cddbb4cd0#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"Foundayo, its once-daily oral GLP-1 pill orforglipron, met…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1de6e-50ce-7eaa-8f6c-b50cddbb4cd0#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-09","isBasedOn":"https://t.me/pattystraphouse/1264","text":"Eli Lilly says Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3 ATTAIN-OSA trial for adults with obesity and moderate-to-severe obstructive sleep apnea.","url":"/claims/01a1de6e-50ce-7eaa-8f6c-b50cddbb4cd0","spokenByCharacter":{"@type":"Person","name":"Eli Lilly","@id":"/actors/01a1d799-ee63-796c-972b-e41e8b55f59a"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.
